Gliknik

Gliknik is a privately held biopharmaceutical company dedicated to alleviating human suffering by creating new therapies for patients with cancer and immune diseases. The Gliknik team combines scientific expertise with commercial acumen and deep experience in the biopharmaceutical industry. Gliknik currently has two novel drugs in clinical trials, with others in preclinical stages. The company shares a common commitment to always strive to do the right thing. Inspired by the desire to apply cutting-edge science to alleviate human suffering, the company’s mission is to discover and develop truly innovative biologics for patients with cancer and immune diseases.